Depressive symptoms in healthy apolipoprotein e e4 carriers and noncarriers

A longitudinal study

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To determine if symptoms of depression accelerate in cognitively normal apolipoprotein E (APOE) e4 carriers as compared to noncarriers. Method: Six hundred thirty-three cognitively and functionally normal members of the Arizona APOE Cohort aged 21-86 years underwent neuropsychological testing every 1 to 2 years that included the Hamilton Depression Rating Scale, the Beck Depression Inventory, the Geriatric Depression Scale, and the Personality Assessment Inventory. We estimated the longitudinal change on these measures using mixed models that simultaneously modeled cross-sectional and longitudinal effects of age on depression scores by APOE status and the interaction between the two. We also estimated incident depression on the basis of accepted clinical cut-scores on depression measures and use of depression medications. Results: The mean length of follow-up was 7.7 years. Comparing APOE e4 carriers with noncarriers revealed no significant longitudinal difference in the rate of change or slope of change on any depression scale or subscale. There was also no difference in incident depression or antidepressant drug use between the carrier and noncarrier groups. Conclusions: These data fail to support a relationship between APOE genotype and longitudinal change in depression symptoms, suggesting that depression symptoms may not be intrinsic to the early preclinical phase of Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)1256-1261
Number of pages6
JournalJournal of Clinical Psychiatry
Volume74
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Apolipoprotein E4
Longitudinal Studies
Depression
Apolipoproteins E
Depressive Symptoms
Carrier
Longitudinal Study
Personality Assessment
Personality Inventory
Geriatrics
Antidepressive Agents
Alzheimer Disease

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)

Cite this

@article{12e296d2a50d4930b8b6fcedc691cb7d,
title = "Depressive symptoms in healthy apolipoprotein e e4 carriers and noncarriers: A longitudinal study",
abstract = "Objective: To determine if symptoms of depression accelerate in cognitively normal apolipoprotein E (APOE) e4 carriers as compared to noncarriers. Method: Six hundred thirty-three cognitively and functionally normal members of the Arizona APOE Cohort aged 21-86 years underwent neuropsychological testing every 1 to 2 years that included the Hamilton Depression Rating Scale, the Beck Depression Inventory, the Geriatric Depression Scale, and the Personality Assessment Inventory. We estimated the longitudinal change on these measures using mixed models that simultaneously modeled cross-sectional and longitudinal effects of age on depression scores by APOE status and the interaction between the two. We also estimated incident depression on the basis of accepted clinical cut-scores on depression measures and use of depression medications. Results: The mean length of follow-up was 7.7 years. Comparing APOE e4 carriers with noncarriers revealed no significant longitudinal difference in the rate of change or slope of change on any depression scale or subscale. There was also no difference in incident depression or antidepressant drug use between the carrier and noncarrier groups. Conclusions: These data fail to support a relationship between APOE genotype and longitudinal change in depression symptoms, suggesting that depression symptoms may not be intrinsic to the early preclinical phase of Alzheimer's disease.",
author = "Locke, {Dona E} and Amylou Dueck and Stonnington, {Cynthia M} and Knopman, {David S} and Geda, {Yonas Endale} and Caselli, {Richard John}",
year = "2013",
month = "12",
doi = "10.4088/JCP.13m08564",
language = "English (US)",
volume = "74",
pages = "1256--1261",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "12",

}

TY - JOUR

T1 - Depressive symptoms in healthy apolipoprotein e e4 carriers and noncarriers

T2 - A longitudinal study

AU - Locke, Dona E

AU - Dueck, Amylou

AU - Stonnington, Cynthia M

AU - Knopman, David S

AU - Geda, Yonas Endale

AU - Caselli, Richard John

PY - 2013/12

Y1 - 2013/12

N2 - Objective: To determine if symptoms of depression accelerate in cognitively normal apolipoprotein E (APOE) e4 carriers as compared to noncarriers. Method: Six hundred thirty-three cognitively and functionally normal members of the Arizona APOE Cohort aged 21-86 years underwent neuropsychological testing every 1 to 2 years that included the Hamilton Depression Rating Scale, the Beck Depression Inventory, the Geriatric Depression Scale, and the Personality Assessment Inventory. We estimated the longitudinal change on these measures using mixed models that simultaneously modeled cross-sectional and longitudinal effects of age on depression scores by APOE status and the interaction between the two. We also estimated incident depression on the basis of accepted clinical cut-scores on depression measures and use of depression medications. Results: The mean length of follow-up was 7.7 years. Comparing APOE e4 carriers with noncarriers revealed no significant longitudinal difference in the rate of change or slope of change on any depression scale or subscale. There was also no difference in incident depression or antidepressant drug use between the carrier and noncarrier groups. Conclusions: These data fail to support a relationship between APOE genotype and longitudinal change in depression symptoms, suggesting that depression symptoms may not be intrinsic to the early preclinical phase of Alzheimer's disease.

AB - Objective: To determine if symptoms of depression accelerate in cognitively normal apolipoprotein E (APOE) e4 carriers as compared to noncarriers. Method: Six hundred thirty-three cognitively and functionally normal members of the Arizona APOE Cohort aged 21-86 years underwent neuropsychological testing every 1 to 2 years that included the Hamilton Depression Rating Scale, the Beck Depression Inventory, the Geriatric Depression Scale, and the Personality Assessment Inventory. We estimated the longitudinal change on these measures using mixed models that simultaneously modeled cross-sectional and longitudinal effects of age on depression scores by APOE status and the interaction between the two. We also estimated incident depression on the basis of accepted clinical cut-scores on depression measures and use of depression medications. Results: The mean length of follow-up was 7.7 years. Comparing APOE e4 carriers with noncarriers revealed no significant longitudinal difference in the rate of change or slope of change on any depression scale or subscale. There was also no difference in incident depression or antidepressant drug use between the carrier and noncarrier groups. Conclusions: These data fail to support a relationship between APOE genotype and longitudinal change in depression symptoms, suggesting that depression symptoms may not be intrinsic to the early preclinical phase of Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=84891480376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891480376&partnerID=8YFLogxK

U2 - 10.4088/JCP.13m08564

DO - 10.4088/JCP.13m08564

M3 - Article

VL - 74

SP - 1256

EP - 1261

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 12

ER -